GlassScriptPhysician profile
Katherine Lavie
NPI 1073812871
$478.26
in general payments reported to CMS, 2019-2025
11 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2021: $169 · 2022: $28.49 · 2023: $34.00 · 2024: $25.68 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $180.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $107.78 | 2019-2023 | Rukobia, Dovato |
| Merck Sharp & Dohme LLC | $81.14 | 2019-2025 | Pifeltro, Capvaxive |
| Janssen Biotech, INC. | $49.58 | 2021 | |
| Melinta Therapeutics, LLC | $47.68 | 2021-2024 | Orbactiv, Kimyrsa, Vabomere |
| Lilly USA, LLC | $36.12 | 2025 | Emgality |
| Insmed, INC. | $34.61 | 2019 | |
| Shionogi INC | $34.37 | 2021 | |
| Abbvie INC. | $28.53 | 2025 | |
| Paratek Pharmaceuticals, INC. | $22.49 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.30 | 2019 | |
| Emd Serono, INC. | $15.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Lavie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.